Skip to main content

Targeting PPARα in low ambient temperature exposure-induced cardiac dysfunction and remodeling

Abstract

The present study demonstrates that the down-regulation of peroxisome proliferator-activated receptor-α (PPARα) results in chronic low ambient temperature (LT) exposure-induced cardiac dysfunction and remodeling, emphasizing the therapeutic potential of PPARα activation strategies (e.g. fenofibrate treatment) in LT-associated cardiac injury.

Dear Editor,

Military agents often patrol and carry out combat missions in high-altitude and extremely cold regions. Long-term exposure to low ambient temperature (LT) leads to cardiac contractile dysfunction and pathological structural remodeling [1]. Unfortunately, the underlying mechanisms remain elusive, and effective therapies are urgently needed. Metabolic reprogramming is widely observed in the diseased heart, which allows the myocardial substrate preference to shift from fatty acids (FAs) to glucose utilization [2]. However, the impact of chronic LT exposure on myocardial substrate metabolism has yet to be defined.

The detailed methods and results are available in Additional file 1. Adult C57BL/6J mice were randomly exposed to room temperature (RT, 24–26 °C) or LT (4 °C) for 8 weeks. We found that myocardial metabolic patterns were robustly changed in LT-stressed mice compared with the RT group. The mRNA levels of genes involved in glycolysis (Hk2, Pfkm, Pkm, Ldha, and Pdk4) were upregulated, whereas the mRNA levels of genes participating in glucose oxidation (Pdha, Pdhb, Idh1, Ogdh, and Suclg2) and FA metabolism (Cd36, Fabp3, Acsl, Cpt1b, Acaa2, and Acadm) were downregulated in the hearts of mice exposed to LT (Additional file 1: Fig. S1a). The detailed sequences of the primers utilized in the study are available in Additional file 1: Table S1. Peroxisome proliferator-activated receptor-α (PPARα) is a nuclear receptor that transcriptionally regulates FA metabolic gene expression in the heart [3]. Compared with the RT group, the mRNA and protein levels of PPARα were markedly downregulated in the hearts of LT-treated mice (Additional file 1: Fig. S1b). To clarify the role of PPARα in LT-associated cardiac injury, Ppara−/− mice and their wild-type (WT) littermates were exposed to RT or LT for 8 weeks. In response to LT, the mRNA levels of genes involved in FA metabolism were much lower in PPARα-deficient hearts than in WT hearts (Additional file 1: Fig. S1c). These results suggest that the downregulation of PPARα contributes to the suppression of FA metabolic gene expression in response to LT. As expected, WT-LT mice exhibited cardiac hypertrophy and lung edema, as indicated by increased heart weight to tibia length ratios (HW/TL) and wet to dry lung weight ratios in comparison to WT-RT mice (Additional file 1: Table S2). Somewhat to our surprise, the cardiac hypertrophy and lung edema were greatly exacerbated in Ppara−/−-LT mice when compared with WT-LT mice (Additional file 1: Table S2). Echocardiography showed that WT-LT mice suffered from cardiac contractile dysfunction, as evidenced by decreased left ventricular ejection fraction (LVEF) and fraction shortening (FS) values (Additional file 1: Table S2). Compared with WT-LT mice, the cardiac contractile dysfunction was markedly aggravated in Ppara−/−-LT mice (Additional file 1: Table S2). Molecular analysis showed that the mRNA levels of fetal (Nppa, Nppb, and Myh7) and profibrotic (Col1a1 and Col3a1) genes were much higher in the hearts of LT-treated Ppara−/− mice than those in WT hearts (Additional file 1: Fig. S1d). Compared with WT controls, the chronic LT exposure-induced cardiomyocyte hypertrophy and interstitial fibrosis were greatly worsened in Ppara−/− mice (Additional file 1: Fig. S1e and f). Together, these data highlight for the first time that the downregulation of PPARα contributes to LT-associated cardiac dysfunction and remodeling.

Next, we investigated whether pharmacological activation of PPARα ameliorates LT-related cardiac injury. C57BL/6J mice were randomized to receive vehicle or fenofibrate [a specific PPARα agonist, 200 mg/(kg day)] when they were exposed to LT [3]. Notably, fenofibrate significantly preserved myocardial FA metabolic gene expression in response to chronic LT exposure (Additional file 1: Fig. S1g). Compared with the vehicle group, fenofibrate ameliorated LT-induced cardiac hypertrophy and lung edema (Additional file 1: Table S3). Fenofibrate markedly eased LT-induced cardiac contractile dysfunction, as evidenced by elevated LVEF and FS values (Additional file 1: Table S3). The upregulation of fetal and profibrotic gene expression induced by LT was greatly attenuated by fenofibrate (Additional file 1: Fig. S1h). Structural analysis showed that fenofibrate mitigated LT-induced cardiomyocyte hypertrophy and interstitial fibrosis (Additional file 1: Fig. S1i). These results demonstrate that pharmacological activation of PPARα might be a promising therapeutic strategy for LT-related cardiomyopathic phenotypes.

LT has been recognized as a neglected health threat for military agents garrisoned in high altitude and high cold regions. Long-term exposure to LT results in cardiac contractile dysfunction and structural remodeling [1]. However, effective therapies are still lacking. FAs are the predominant energy substrates utilized by the heart, and impaired FA metabolism due to the downregulation of PPARα has been widely observed in the failing heart [2]. PPARα-null hearts are protected against ischemia/reperfusion injury and ischemic cardiomyopathy because PPARα deletion suppresses myocardial FA oxidation, reduces the generation of lipotoxic molecules and reactive oxygen species, ameliorates cardiomyocyte apoptosis, and ultimately limits the expansion of the infarcted area [4]. In contrast, in hearts stressed by non-ischemic insults, the downregulation of PPARα results in insufficient energy supply, worsens cardiac dysfunction, and accelerates the development of heart failure [5]. Here, utilizing genetic mouse models, we provide solid evidence demonstrating for the first time that the downregulation of PPARα is responsible for LT-related cardiac dysfunction and remodeling. More importantly, the present work highlights that the activation of PPARα via clinically available drugs (e.g., fenofibrate) might be a novel and promising strategy for the treatment of LT-related cardiac injury.

Availability of data and materials

Detailed methods and supplementary data are available in online Additional file.

Abbreviations

Acaa2:

Acetyl-CoA acetyltransferase-2

Acadm:

Medium-chain specific acyl-CoA dehydrogenase

Acsl:

Long-chain acyl-CoA synthetase

Col1α1:

Collagen, type I, alpha 1

Col3α1:

Collagen, type III, alpha 1

Cpt1b:

Carnitine palmitoyltransferase 1b

FA:

Fatty acid

Fabp3:

Fatty acid binding protein-3

Hk2:

Hexokinase-2

HW:

Heart weight

HF:

Heart failure

KO:

Knockout

mRNA:

Messenger RNA

Myh7:

Myosin heavy chain-7

Nppa:

Natriuretic peptide precursor a

Nppb:

Natriuretic peptide precursor b

PPARα:

Peroxisome proliferator activated receptor-α

TL:

Tibia length

WT:

Wild-type

References

  1. 1.

    Yin Z, Ding G, Chen X, Qin X, Xu H, Zeng B, et al. Beclin1 haploinsufficiency rescues low ambient temperature-induced cardiac remodeling and contractile dysfunction through inhibition of ferroptosis and mitochondrial injury. Metabolism. 2020;113:154397.

    CAS  Article  Google Scholar 

  2. 2.

    Colin S, Briand O, Touche V, Wouters K, Baron M, Pattou F, et al. Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production. Eur Heart J. 2013;34(32):2566–74.

    CAS  Article  Google Scholar 

  3. 3.

    Zhang F, Wang K, Zhang S, Li J, Fan R, Chen X, et al. Accelerated FASTK mRNA degradation induced by oxidative stress is responsible for the destroyed myocardial mitochondrial gene expression and respiratory function in alcoholic cardiomyopathy. Redox Biol. 2021;38:101778.

    CAS  Article  Google Scholar 

  4. 4.

    Li Y, Xiong Z, Yan W, Gao E, Cheng H, Wu G, et al. Branched chain amino acids exacerbate myocardial ischemia/reperfusion vulnerability via enhancing GCN2/ATF6/PPAR-α pathway-dependent fatty acid oxidation. Theranostics. 2020;10(12):5623–40.

    CAS  Article  Google Scholar 

  5. 5.

    Zhang F, Xia Y, Yan W, Zhang H, Zhou F, Zhao S, et al. Sphingosine 1-phosphate signaling contributes to cardiac inflammation, dysfunction, and remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol. 2016;310(2):H250–61.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (81800326), the Innovation and Cultivation Fund of the 7th Medical Center of Chinese PLA General Hospital, the Open Project of State Key Laboratory of Military Stomatology (2018KA02), and the Military Medical Science and Technology Youth Training Program (21QNPY116).

Author information

Affiliations

Authors

Contributions

FYZ designed and supervised the overall study and provided the funding support. XYC drafted the manuscript, performed the study and analyzed the data. YJ provided the technical and fund support. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Fu-Yang Zhang.

Ethics declarations

Ethics approval and consent to participate

The animal study was approved by the Animal Care and Use Committee of Air Force Medical University (No. 2019-0821-7).

Consent for publication

No applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Fig. S1.

Role of PPARα in LT-related cardiac injury. Table S1. Primer sequence for RT-PCR. Table S2. General biometric and echocardiographic properties of WT and Ppara−/− mice upon 8-week room temperature or low ambient exposure. Table S3. General biometric and echocardiographic properties of C57BL/6J mice received vehicle or fenofibrate treatment upon 8-wk room temperature or low ambient temperature exposure.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, XY., Jiao, Y. & Zhang, FY. Targeting PPARα in low ambient temperature exposure-induced cardiac dysfunction and remodeling. Military Med Res 8, 53 (2021). https://doi.org/10.1186/s40779-021-00347-y

Download citation

Keywords

  • Low ambient temperature
  • Cardiac dysfunction
  • Remodeling
  • Peroxisome proliferator-activated receptor-α
  • Fatty acid metabolism